BIRC5 and neoplasm: Adjuvant support guarantees that APCs provide enough costimulatory signals to trigger a strong T-cell response.166 Peptide vaccines exploiting tumor-associated antigens (TAAs), such as EGFRvIII, IDH1-R132H, or survivin, have been studied in various clinical trials.